The Development of Immune-based Therapies Using Plant Derived Compounds to Attenu

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43AI087308-01A1
Agency Tracking Number: AI087308
Amount: $99,974.00
Phase: Phase I
Program: SBIR
Awards Year: 2010
Solicitation Year: 2010
Solicitation Topic Code: NIAID
Solicitation Number: PHS2010-2
Small Business Information
DUNS: 783987774
HUBZone Owned: N
Woman Owned: Y
Socially and Economically Disadvantaged: N
Principal Investigator
 () -
Business Contact
Phone: (314) 517-8837
Research Institution
DESCRIPTION (provided by applicant): Secondary metabolites will be extracted from a specific plant material to identify and isolate immune active components. These components are proposed to enhance the innate and adaptive immune systems by modulating certain cytokine levels in white blood cells before the progression of Human Immunodeficiency Virus (HIV) to Acquired Immune Deficiency Syndrome (AIDS) occurs. The components identified will be used to develop new anti-HIV immune-based therapies. The plant material containing the components with desirable immune active characteristics has been identified. The methods suitable for extraction of secondary metabolites (non-polymeric small molecules) from the plant material and antibody-based assay for testing of human cytokines in white blood cells have been established. Phase I of this project includes identification and isolation of immune active components from the plant extract using reverse phase High Performance Liquid Chromatography (HPLC), Ion-Exchange Chromatography (IEC), Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS). The percentage of active components in the plant will be determined. Phase II of the project will entail either large scale isolation/purification or synthesis of identified immune active plant components to develop screens for new anti-HIV immune-based therapies both in vitro and in vivo. The therapies proposed can reduce viral load and indirectly lower the resistance of HIV to current antiviral drugs. PUBLIC HEALTH RELEVANCE: The project seeks to isolate immune active components from specific plants that can modulate certain cytokine levels in human white blood cells which would provide an immune-based therapeutic activity to attenuate HIV progression. The end result of this project would have substantial commercial potential as a frontline therapy and synergistic compound that can indirectly lower the resistance of HIV to current antiviral drugs. We believe that our potential product will be used either alone, as an initial therapy for newly diagnosed patients, or in combination with current antiviral drugs.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government